- Conditions
- IBS - Irritable Bowel Syndrome
- Interventions
- Psilocybin 25 mg, Psychotherapy Treatment Session, Niacin 100 mg
- Drug · Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 1,252
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma
- Interventions
- rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Omaha, Nebraska
- Conditions
- Migraine, Without Aura
- Interventions
- sumatriptan succinate / naproxen sodium, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 70
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
- Conditions
- Acute Leukemias of Ambiguous Lineage, B-cell Adult Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma
- Interventions
- cyclophosphamide, vincristine sulfate, prednisone, inotuzumab ozogamicin, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 5
- States / cities
- Duarte, California • Palo Alto, California • Rochester, New York + 2 more
- Conditions
- Migraine Headache
- Interventions
- Psilocybin, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Heart Failure, Sleep Disorders
- Interventions
- melatonin, placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rhabdomyosarcoma
- Interventions
- Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- rituximab, prednisone, cyclophosphamide, doxorubicin, vincristine, indium In 111 ibritumomab tiuxetan, radiation therapy, positron emission tomography
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase, L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Epcoritamab, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 68
- States / cities
- Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more
- Conditions
- QTc Interval, Pharmacokinetics
- Interventions
- Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
- Drug
- Lead sponsor
- Usona Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Delirium
- Interventions
- Melatonin, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Desmoplastic/Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma With Extensive Nodularity, Nevoid Basal Cell Carcinoma Syndrome
- Interventions
- Carboplatin, Cognitive Assessment, Cyclophosphamide, Etoposide, Laboratory Biomarker Analysis, Methotrexate, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 47 Months
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 126 more
- Conditions
- Rhabdomyosarcoma
- Interventions
- Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide Pill
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 15 more
- Conditions
- Kidney Cancer
- Interventions
- aldesleukin, sargramostim, vinblastine sulfate
- Biological · Drug
- Lead sponsor
- Hope Cancer Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas
- Conditions
- Leukemia, Lymphoma
- Interventions
- cytarabine, decitabine, doxorubicin hydrochloride, imatinib mesylate, methotrexate, pegaspargase, prednisone, vincristine sulfate, vorinostat
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Cytarabine, Vinblastine/prednisone
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Palo Alto, California • San Diego, California • Minneapolis, Minnesota + 8 more
- Conditions
- Pediatric, Hodgkin's Disease
- Interventions
- COPP/ABV, intensive chemo with concurrent growth factor
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Migraine in Adolescents
- Interventions
- Melatonin, Placebo
- Drug · Other
- Lead sponsor
- Amy Gelfand
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Vinorelbine, Docetaxel, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Lymphoma
- Interventions
- rituximab, bendamustine hydrochloride, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, methotrexate, vincristine sulfate
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 204
- States / cities
- Duarte, California • Aurora, Colorado • Boulder, Colorado + 142 more
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Marqibo® (vincristine sulfate liposomes injection)
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 11 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Duarte, California + 38 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Metformin, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Intrathecal chemotherapy
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • St. Petersburg, Florida + 2 more